Company Monitoring Page for Eli-Lilly

latest headlines for company on cafepharma

Insider alleges Eli Lilly blocked her efforts to sound alarms about U.S. drug factory
Reuters
Sun, 03/14/21 - 11:03 pm
Tags:
Eli Lilly, drug manufacturing, Trulicity
Lilly rejoins KRAS race with swipe at Amgen and Mirati, plans 2021 clinical trial
Fierce Biotech
Thu, 03/11/21 - 10:47 am
Tags:
Eli Lilly, KRAS, Amgen, Mirati Therapeutics, LY3499446, solid tumors
Lilly lines up its next shot at Alzheimer’s
EP Vantage
Thu, 03/11/21 - 10:39 am
Tags:
Eli Lilly, donanemab, Alzheimer's disease
Eli Lilly COVID-19 antibody combo aces study, cutting hospitalizations and deaths by a whopping 87%
Fierce Pharma
Wed, 03/10/21 - 11:24 am
Tags:
Eli Lilly, antibodies, FDA, bamlanivimab-etesevimab, COVID-19
Lilly, Biolojic to develop antibody therapies for diabetes treatment
Pharmaceutical Business Review
Tue, 03/9/21 - 10:33 am
Tags:
Eli Lilly, Biolojic Design, diabetes, R&D
AI uncovers Eli Lilly's rheumatoid arthritis drug Olumiant as potential Alzheimer's treatment
Fierce Biotech
Mon, 03/8/21 - 10:42 am
Tags:
Eli Lilly, olumiant, JAK inhibitors, artificial intelligence, Alzheimer's disease
Lilly has its Ozempic-beating data from a head-to-head diabetes trial. Should Novo Nordisk be worried?
Fierce Pharma
Sun, 03/7/21 - 01:27 pm
Tags:
Eli Lilly, tirzepatide, diabetes, Ozempic, Novo Nordisk, clinical trials
Lilly's tirzepatide beats Novo's semaglutide in diabetes phase 3, but another study muddies picture
Fierce Biotech
Thu, 03/4/21 - 10:05 am
Tags:
Eli Lilly, Novo Nordisk, tirzepatide, semaglutide, type 2 diabetes, clinical trials
Eli Lilly, Incyte Report Positive Results For Baricitinib In Alopecia Areata Treatment
NASDAQ
Wed, 03/3/21 - 10:53 am
Tags:
Eli Lilly, Incyte, baricitinib, alopecia areata
Look for Eli Lilly's Verzenio to hit $4.6B, thanks to early breast cancer win: analyst
Fierce Pharma
Tue, 03/2/21 - 12:12 pm
Tags:
Eli Lilly, Verzenio, breast cancer, early breast cancer
Lilly scores $210M supply deal for newly authorized coronavirus antibody cocktail
Fierce Pharma
Sun, 02/28/21 - 11:56 pm
Tags:
Eli Lilly, antibodies, COVID-19, government contract
Merck inks $1.9B Pandion takeover to square up against Amgen, Lilly and Roche
Fierce Biotech
Thu, 02/25/21 - 10:44 am
Tags:
Merck, Pandion, M&A, immune modulators, Amgen, Eli Lilly, Roche
Watch out, Novo Nordisk. Lilly's new dual action diabetes med could pressure Ozempic: analyst
Fierce Pharma
Tue, 02/23/21 - 10:56 pm
Tags:
Eli Lilly, tirzepatide, Novo Nordisk, Ozempic, diabetes
Eli Lilly's David Ricks snared $24M pay package in a year turbo-boosted by Covid-19 antibody
Endpoints
Mon, 02/22/21 - 10:47 am
Tags:
Eli Lilly, David Ricks, executive pay, Pharma CEOs, pandemic, COVID-19
Lilly wagers almost $1B on Rigel's drugs for immune and nervous systems
BioPharma Dive
Thu, 02/18/21 - 10:05 pm
Tags:
Eli Lilly, Rigel Pharmaceuticals, autoimmune disease, inflammatory disease
Lilly's tirzepatide aces 2 more late-phase diabetes trials
Fierce Biotech
Wed, 02/17/21 - 11:01 am
Tags:
Eli Lilly, tirzepatide, type 2 diabetes, clinical trials
Ousted Eli Lilly CFO Loses $24 Million in Potential Pay
BioSpace
Sat, 02/13/21 - 10:56 pm
Tags:
Eli Lilly, Josh Smiley, executive pay
Eli Lilly scores FDA nod for COVID-19 antibody cocktail, aims to make 1M doses by midyear
Fierce Pharma
Wed, 02/10/21 - 10:16 am
Tags:
Eli Lilly, COVID-19, antibodies, FDA, Emergency Use Authorization
Eli Lilly's chief financial officer resigned after a misconduct investigation revealed he sent 'consensual though inappropriate' personal messages to employees
Business Insider
Tue, 02/9/21 - 12:44 pm
Tags:
Eli Lilly, inappropriate conduct
Lilly cancer R&D chief Bilenker quits, handing reins to deputy
Fierce Biotech
Tue, 02/2/21 - 11:09 pm
Tags:
Eli Lilly, R&D, Josh Bilenker, Loxo Oncology

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.